Compare TORO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TORO | CGEN |
|---|---|---|
| Founded | 2022 | 1993 |
| Country | Cyprus | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.8M | 191.1M |
| IPO Year | 2022 | 2001 |
| Metric | TORO | CGEN |
|---|---|---|
| Price | $4.97 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 33.7K | ★ 301.9K |
| Earning Date | 04-15-2026 | 05-18-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.16 | $1.30 |
| 52 Week High | $8.50 | $3.24 |
| Indicator | TORO | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 58.87 |
| Support Level | $4.89 | $1.48 |
| Resistance Level | $5.85 | $3.05 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 36.99 | 97.95 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.